Anti-tumour necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease

Núñez-Gómez, Laura; Mesonero-Gismero, Francisco; Albillos-Martínez, Agustin; López-Sanromán, Antonio

doi:10.1016/j.gastre.2018.06.014

Cited by 2 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there are many data showing the efficacy of antiTNF agents in the treatment of IBD, data are limited regarding the effectiveness of antiTNF agents on anemia which is the most common systemic complication of IBD. [ 10 ] Anemia in IBD may develop due to many factors such as blood loss due to mucosal damage, dietary factors and inflammatory changes during active disease. As is known, inflammatory cytokines (especially TNF-α) adversely affect duodenal iron absorption via hepcidin and inhibit erythropoiesis with their systemic effects on bone marrow stem cells.…”

Section: Discussionmentioning

confidence: 99%

Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease

et al. 2022

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is characterized by many clinical features. Anemia is 1 of the most frequent complications and/or extraintestinal manifestations of IBD. There are conflicting data regarding the relationship between changes in hemoglobin levels and disease prevalence in IBD patients with and without antitumor necrosis factor (antiTNF) therapy. In our study, we aimed to investigate the long-term effect of antiTNF agents on anemia in IBD. The records of IBD patients followed-up in our hospital between January 2011 and January 2021 were reviewed retrospectively. Demographic, clinical, endoscopic, radiological and medical treatment data of the patients were recorded. Complete blood count and laboratory markers of inflammation and disease activation, were recorded at the beginning and at the first year of treatment in all patients. The data of patients with and without antiTNF therapy were analyzed statistically. A total of 240 IBD patients who met the inclusion criteria were enrolled in the study. The number of patients with and without antiTNF therapy was 102 (42.5%) and 138 (57.5%), respectively. The change in all laboratory parameters between the beginning and the first year of treatment was statistically significant (P < .001) in all IBD patients with and without antiTNF therapy. The change in Hb level after 1 year of treatment was significantly different in patients with antiTNF therapy compared to those without therapy (3.00 ± 1.78 g/dL vs 1.19 ± 1.38 g/dL, P < .001). In the multiple regression analysis, male gender, antiTNF therapy, baseline Hb level and iron therapy were independent significant variables of hematopoietic response. This study showed that with appropriate treatment, hemoglobin levels of IBD patients with and without antiTNF therapy increased within 1 year, and the use of antiTNF agents in the treatment of IBD was an independent variable in correcting anemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…determined that the separation of IBD between ileal CD, colonic CD and UC could be considered as a continuum of phenotypes, to which specific risk score could be applied ( Cleynen et al., 2016 ). Concerning disease behavior, better results were obtained in CD with anti-TNF agents in patients with non-stricturing, non-penetrating disease (B1 according to the Montréal classification), as compared to stricturing disease (B2) or fistulizing disease (B3) ( Moran et al., 2014 ; Bouhnik et al., 2018 ; Nunez-Gomez et al., 2018 ). In UC, only limited data are available to guide therapy of isolated proctitis with biological agents.…”

Section: Personalizing Choice Of Biologicmentioning

confidence: 99%

Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?

Juillerat

Grueber

Ruetsch

et al. 2022

Current Research in Pharmacology and Drug Discovery

View full text Add to dashboard Cite

Anti-tumour necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease

Cited by 2 publications

References 49 publications

Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease

Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease

Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?

Contact Info

Product

Resources

About